Dr. Christopher Heaphy is a dedicated cancer biologist whose research combines tissue-based, cell-based, and molecular approaches to investigate the role of telomere alterations in human diseases, with a primary focus on cancer, including prostate cancer, pancreatic neuroendocrine tumors, breast cancer, sarcomas, and gliomas. His lab conducts both basic and translational research aimed at understanding how these alterations contribute to the initiation and progression of cancer.
The overarching goal of Dr. Heaphy's research program is to leverage molecular insights from the tumor and its microenvironment to advance clinical applications. His work aims to develop strategies for accurately predicting cancer risk, prognosis, and the potential response to targeted therapies.
Dr. Heaphy earned his Ph.D. from the University of New Mexico School of Medicine and completed postdoctoral training at the Johns Hopkins University School of Medicine. Currently, he is an Associate Professor of Medicine affiliated with Boston Medical Center and a member of the Boston University-Boston Medical Center (BU-BMC) Cancer Center.
Diversity, Equity, Inclusion and Accessibility
Coming from diverse Hispanic and Irish backgrounds, I am dedicated to advancing inclusion and equality for all. My passion lies in fostering diversity and inclusion within academia and medicine. For instance, I have actively supported gender equity in medicine through the Women in NETs (WIN) initiative of the North American Neuroendocrine Tumor Society (NANETS), where I also chair the Scientific Review & Research Committee. Additionally, I have mentored undergraduate students in the Boston University STaRS program. This NIH-funded initiative aims to enhance access to graduate and medical education for historically underrepresented students in science and medicine.
My research at Boston Medical Center aligns with our mission of ‘exceptional care without exception’, particularly addressing racial disparities in cancer outcomes. For example, disparities in prostate cancer incidence and outcomes are well-documented. Factors such as screening, access to care, and treatment plans exhibit significant race-based inequities. Recent studies have shown that adjusting for social determinants of health—such as education, neighborhood, healthcare access, socioeconomic status, and medical literacy—can completely attenuate higher prostate cancer-specific mortality risks among Black men previously attributed to biological differences. Currently, our collaborative research integrates racial, molecular, metabolic, and geographic factors to redefine risk of progression. Our goal is to identify new clinical and social determinants of health data to develop a comprehensive risk signature. This signature will guide personalized care pathways, integrating clinical treatment with patient navigation to improve coordination and outcomes.
Member
Boston University
BU-BMC Cancer Center
Member
Boston University
Evans Center for Interdisciplinary Biomedical Research
Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy08/22/2023 - 07/31/2026 (PI)
Johns Hopkins University National Cancer Inst
The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy08/22/2023 - 07/31/2026 (PI)
Johns Hopkins University
Defining genetic vulnerabilities in pancreatic neuroendocrine tumors that rely on the alternative lengthening of telomeres pathway08/01/2023 - 07/31/2026 (PI)
Department of the Army
Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors01/01/2024 - 12/31/2025 (PI)
National Cancer Institute/NIH/DHHS1R21CA286402-01
Spatial transcriptomic profiling of the PanNET tumor microenvironment01/03/2023 - 01/02/2025 (PI)
Neuroendocrine Tumor Research Foundation
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy01/01/2021 - 12/31/2024 (PI)
Johns Hopkins University National Cancer Inst5R01CA255349-03
Highly resolved spatial mapping of pancreatic neuroendocrine tumors for intra- and inter-tumor variability09/01/2023 - 08/31/2024 (PI)
Department of Defense
|
Yr
|
Title
|
Project-Sub Proj
|
Pubs
|
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Sung YN, Stojanova M, Shin S, Cho H, Heaphy CM, Hong SM. Gradual telomere shortening in the tumorigenesis of pancreatic and hepatic mucinous cystic neoplasms. Hum Pathol. 2024 Oct; 152:105653. PMID: 39214240
-
Graham MK, Xu B, Davis C, Meeker AK, Heaphy CM, Yegnasubramanian S, Dyer MA, Zeineldin M. The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. Cancer Res Commun. 2024 Jun 20; 4(6):1533-1547. PMID: 38837897; PMCID: PMC11188873; DOI: 10.1158/2767-9764.CRC-22-0287;
-
-
Pinto LM, Pailas A, Bondarchenko M, Sharma AB, Neumann K, Rizzo AJ, Jeanty C, Nicot N, Racca C, Graham MK, Naughton C, Liu Y, Chen CL, Meakin PJ, Gilbert N, Britton S, Meeker AK, Heaphy CM, Larminat F, Van Dyck E. DAXX promotes centromeric stability independently of ATRX by preventing the accumulation of R-loop-induced DNA double-stranded breaks. Nucleic Acids Res. 2024 Feb 09; 52(3):1136-1155. PMID: 38038252; PMCID: PMC10853780; DOI: 10.1093/nar/gkad1141;
-
Mori JO, Keegan J, Flynn RL, Heaphy CM. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer. J Clin Pathol. 2024 Jan 18; 77(2):82-86.View Related Profiles. PMID: 37890990
-
Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nat Rev Urol. 2024 May; 21(5):258-273.View Related Profiles. PMID: 37907729; PMCID: PMC11058122; DOI: 10.1038/s41585-023-00827-x;
-
Ertunc O, Smearman E, Zheng Q, Hicks JL, Brosnan-Cashman JA, Jones T, Gomes-Alexandre C, Trabzonlu L, Meeker AK, De Marzo AM, Heaphy CM. Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate. Prostate. 2024 Feb; 84(2):148-157. PMID: 37849074; PMCID: PMC10843147; DOI: 10.1002/pros.24633;
-
Neyaz A, Crotty R, Rickelt S, Pankaj A, Stojanova M, Michelakos TP, Sekigami Y, Kontos F, Parrack PH, Patil DT, Heaphy CM, Ferrone CR, Deshpande V. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT). Histopathology. 2023 Oct; 83(4):546-558. PMID: 37455385
-
Ertunc O, Smearman E, Zheng Q, Hicks JL, Brosnan-Cashman JA, Jones T, Gomes-Alexandre C, Trabzonlu L, Meeker AK, De Marzo AM, Heaphy CM. Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate. bioRxiv. 2023 Apr 06. PMID: 37066381; PMCID: PMC10104079; DOI: 10.1101/2023.04.04.535575;
-
Heaphy CM, Singhi AD. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs). Hum Pathol. 2023 Feb; 132:1-11. PMID: 36702689; PMCID: PMC10259096; DOI: 10.1016/j.humpath.2023.01.004;
Showing 10 of 111 results.
Show More
-
Jafari N, Chen A, Kolla M, Pompa IR, Qiu Y, Yu R, Llevenes P, Ennis CS, Mori J, Mahdaviani K, Halpin M, Gignac GA, Heaphy CM, Monti S, Denis GV. Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. Adv Cancer Biol Metastasis. 2022 Dec; 6.View Related Profiles. PMID: 36644690; PMCID: PMC9836031; DOI: 10.1016/j.adcanc.2022.100073;
-
Low JY, Ko M, Hanratty B, Patel RA, Bhamidipati A, Heaphy CM, Sayar E, Lee JK, Li S, De Marzo AM, Nelson WG, Gupta A, Yegnasubramanian S, Ha G, Epstein JI, Haffner MC. Genomic Characterization of Prostatic Basal Cell Carcinoma. Am J Pathol. 2023 Jan; 193(1):4-10. PMID: 36309102; PMCID: PMC9768679; DOI: 10.1016/j.ajpath.2022.09.010;
-
-
Heaphy CM, Singhi AD. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol. 2022 Nov; 129:11-20. PMID: 35872157
-
Heaphy CM, Joshu CE, Barber JR, Davis C, Lu J, Zarinshenas R, Giovannucci E, Mucci LA, Stampfer MJ, Han M, De Marzo AM, Lotan TL, Platz EA, Meeker AK. The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. J Pathol Clin Res. 2022 Sep; 8(5):481-491. PMID: 35836303; PMCID: PMC9353659; DOI: 10.1002/cjp2.288;
-
Yuan M, Eberhart CG, Pratilas CA, Blakeley JO, Davis C, Stojanova M, Reilly K, Meeker AK, Heaphy CM, Rodriguez FJ. Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors. Cancers (Basel). 2022 Jun 19; 14(12). PMID: 35740680; PMCID: PMC9221513; DOI: 10.3390/cancers14123015;
-
Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R. Correction: Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clin Cancer Res. 2022 Apr 14; 28(8):1737. PMID: 35419593
-
Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate. 2022 Jun; 82(10):1005-1015.View Related Profiles. PMID: 35403746; PMCID: PMC11134172; DOI: 10.1002/pros.24351;
-
Lally SE, Milman T, Orloff M, Dalvin LA, Eberhart CG, Heaphy CM, Rodriguez FJ, Lin CC, Dockery PW, Shields JA, Shields CL. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. Ophthalmology. 2022 Jun; 129(6):679-693. PMID: 35085662
-
Dreijerink KM, Hackeng WM, Singhi AD, Heaphy CM, Brosens LA. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. J Pathol. 2022 02; 256(2):143-148. PMID: 34750813
-
Shrestha E, Coulter JB, Guzman W, Ozbek B, Hess MM, Mummert L, Ernst SE, Maynard JP, Meeker AK, Heaphy CM, Haffner MC, De Marzo AM, Sfanos KS. Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. Proc Natl Acad Sci U S A. 2021 08 10; 118(32). PMID: 34341114; PMCID: PMC8364155; DOI: 10.1073/pnas.2018976118;
-
Heaphy CM, VandenBussche CJ. Prognostic biomarkers in pancreatic neuroendocrine tumors. Cancer Cytopathol. 2021 11; 129(11):841-843. PMID: 34242496
-
Kang HJ, Oh JH, Kim YW, Kim W, An J, Sung CO, Kim J, Shim JH, Hwang S, Yu E, Heaphy CM, Hong SM. Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver Int. 2021 10; 41(10):2499-2510. PMID: 34036718
-
Brosnan-Cashman JA, Davis CM, Diplas BH, Meeker AK, Rodriguez FJ, Heaphy CM. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. Mod Pathol. 2021 10; 34(10):1810-1819. PMID: 34103668
-
Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2022 May; 71(5):961-973. PMID: 33849943; PMCID: PMC8511349; DOI: 10.1136/gutjnl-2020-322595;
-
Hempel Sullivan H, Maynard JP, Heaphy CM, Lu J, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. J Pathol. 2021 04; 253(4):415-426. PMID: 33338262
-
Joshu CE, Heaphy CM, Barber JR, Lu J, Zarinshenas R, Davis C, Han M, Lotan TL, Sfanos KS, De Marzo AM, Meeker AK, Platz EA. Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer. Cancer Prev Res (Phila). 2021 04; 14(4):463-470. PMID: 33355185; PMCID: PMC8026488; DOI: 10.1158/1940-6207.CAPR-20-0250;
-
Pieterman CRC, Sadowski SM, Maxwell JE, Katz MHG, Lines KE, Heaphy CM, Tirosh A, Blau JE, Perrier ND, Lewis MA, Metzcar JP, Halperin DM, Thakker RV, Valk GD. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. Endocr Relat Cancer. 2020 08; 27(8):T9-T25. PMID: 32069215
-
Hackeng WM, Schelhaas W, Morsink FHM, Heidsma CM, van Eeden S, Valk GD, Vriens MR, Heaphy CM, Nieveen van Dijkum EJM, Offerhaus GJA, Dreijerink KMA, Brosens LAA. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocr Pathol. 2020 Jun; 31(2):108-118. PMID: 32103422; PMCID: PMC7250793; DOI: 10.1007/s12022-020-09611-8;
-
Esopi D, Graham MK, Brosnan-Cashman JA, Meyers J, Vaghasia A, Gupta A, Kumar B, Haffner MC, Heaphy CM, De Marzo AM, Meeker AK, Nelson WG, Wheelan SJ, Yegnasubramanian S. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. Cell Oncol (Dordr). 2020 Oct; 43(5):847-861. PMID: 32468444; PMCID: PMC7581602; DOI: 10.1007/s13402-020-00531-7;
-
Heaphy CM, Haffner MC, Graham MK, Lim D, Davis C, Corey E, Epstein JI, Eisenberger MA, Wang H, De Marzo AM, Meeker AK, Lotan TL. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Hum Pathol. 2020 07; 101:70-79. PMID: 32389660; PMCID: PMC7321874; DOI: 10.1016/j.humpath.2020.04.014;
-
Heaphy CM, Bi WL, Coy S, Davis C, Gallia GL, Santagata S, Rodriguez FJ. Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. Mod Pathol. 2020 08; 33(8):1475-1481. PMID: 32203094; PMCID: PMC8867890; DOI: 10.1038/s41379-020-0523-2;
-
Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Chianchiano P, Gobbo S, Regi P, Salvia R, Bassi C, He J, Weiss MJ, Cameron JL, Offerhaus GJA, Hruban RH, Lawlor RT, Scarpa A, Heaphy CM, Wood LD, Wolfgang CL. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Ann Surg. 2020 03; 271(3):566-573. PMID: 30339629; PMCID: PMC6565500; DOI: 10.1097/SLA.0000000000003022;
-
Kim JY, Brosnan-Cashman JA, Kim J, An S, Lee KB, Kim H, Park DY, Jang KT, Oh YH, Hruban RH, Heaphy CM, Hong SM. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours. Pathology. 2020 Apr; 52(3):336-347. PMID: 32111396
-
Felsenstein M, Trujillo MA, Huang B, Nanda N, Jiang Z, Jeong YJ, Pflüger M, Goggins MG, Hruban RH, Thompson ED, Heaphy CM, Roberts NJ, Wood LD. Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. Lab Invest. 2020 07; 100(7):1003-1013. PMID: 32005909; PMCID: PMC7316603; DOI: 10.1038/s41374-020-0372-0;
-
Hempel Sullivan H, Heaphy CM, Kulac I, Cuka N, Lu J, Barber JR, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes. Cancer Epidemiol Biomarkers Prev. 2020 03; 29(3):668-675. PMID: 31932412
-
Heaphy CM, Joshu CE, Barber JR, Davis C, Zarinshenas R, De Marzo AM, Lotan TL, Sfanos KS, Meeker AK, Platz EA. Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes. Cancer Epidemiol Biomarkers Prev. 2020 03; 29(3):676-680. PMID: 31915143; PMCID: PMC7060118; DOI: 10.1158/1055-9965.EPI-19-1462;
-
Hackeng WM, Morsink FHM, Moons LMG, Heaphy CM, Offerhaus GJA, Dreijerink KMA, Brosens LAA. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration. Diagn Cytopathol. 2020 Apr; 48(4):308-315. PMID: 31846235; PMCID: PMC7079001; DOI: 10.1002/dc.24368;
-
Graham MK, Kim J, Da J, Brosnan-Cashman JA, Rizzo A, Baena Del Valle JA, Chia L, Rubenstein M, Davis C, Zheng Q, Cope L, Considine M, Haffner MC, De Marzo AM, Meeker AK, Heaphy CM. Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells. Mol Cancer Res. 2019 12; 17(12):2480-2491. PMID: 31611308; PMCID: PMC6891209; DOI: 10.1158/1541-7786.MCR-19-0654;
-
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 Oct; 25(10):1627.View Related Profiles. PMID: 31501535
-
Tomasetti C, Poling J, Roberts NJ, London NR, Pittman ME, Haffner MC, Rizzo A, Baras A, Karim B, Kim A, Heaphy CM, Meeker AK, Hruban RH, Iacobuzio-Donahue CA, Vogelstein B. Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20482-20488. PMID: 31548407; PMCID: PMC6789572; DOI: 10.1073/pnas.1905722116;
-
Flynn RL, Heaphy CM. Surviving Telomere Attrition with the MiDAS Touch. Trends Genet. 2019 11; 35(11):783-785.View Related Profiles. PMID: 31526614
-
Rodriguez FJ, Graham MK, Brosnan-Cashman JA, Barber JR, Davis C, Vizcaino MA, Palsgrove DN, Giannini C, Pekmezci M, Dahiya S, Gokden M, Noë M, Wood LD, Pratilas CA, Morris CD, Belzberg A, Blakeley J, Heaphy CM. Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathol Commun. 2019 08 28; 7(1):139. PMID: 31462295; PMCID: PMC6712691; DOI: 10.1186/s40478-019-0792-5;
-
Asaka S, Davis C, Lin SF, Wang TL, Heaphy CM, Shih IM. Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. Am J Surg Pathol. 2019 08; 43(8):1083-1091. PMID: 31107721; PMCID: PMC6629487; DOI: 10.1097/PAS.0000000000001283;
-
Martínez H, Nagurney M, Wang ZX, Eberhart CG, Heaphy CM, Curtis MT, Rodriguez FJ. ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation. J Neuropathol Exp Neurol. 2019 Aug 01; 78(8):703-708. PMID: 31225581; PMCID: PMC6640895; DOI: 10.1093/jnen/nlz050;
-
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019 08; 25(8):1260-1265.View Related Profiles. PMID: 31263286; PMCID: PMC6919319; DOI: 10.1038/s41591-019-0493-4;
-
Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM. Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harb Perspect Med. 2019 04 01; 9(4). PMID: 30082453; PMCID: PMC6444695; DOI: 10.1101/cshperspect.a030403;
-
Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA. Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clin Chem. 2019 01; 65(1):189-198. PMID: 30518666; PMCID: PMC7375195; DOI: 10.1373/clinchem.2018.293365;
-
Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM. Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. Eur Urol Oncol. 2019 07; 2(4):429-436. PMID: 31277779; PMCID: PMC7039332; DOI: 10.1016/j.euo.2018.09.014;
-
Rodriguez FJ, Brosnan-Cashman JA, Allen SJ, Vizcaino MA, Giannini C, Camelo-Piragua S, Webb M, Matsushita M, Wadhwani N, Tabbarah A, Hamideh D, Jiang L, Chen L, Arvanitis LD, Alnajar HH, Barber JR, Rodríguez-Velasco A, Orr B, Heaphy CM. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathol. 2019 01; 29(1):126-140. PMID: 30192422; PMCID: PMC6314894; DOI: 10.1111/bpa.12646;
-
Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. PLoS One. 2018; 13(9):e0204159. PMID: 30226859; PMCID: PMC6143253; DOI: 10.1371/journal.pone.0204159;
-
-
Kwon JH, Kim HJ, Park DH, Lee YJ, Heaphy CM, Klöppel G, Hruban RH, Hong SM. Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis. Virchows Arch. 2018 Nov; 473(5):649-653. PMID: 30003325; DOI: 10.1007/s00428-018-2407-0;
-
Weber KA, Heaphy CM, Joshu CE, Lu J, Rohrmann S, Bienstock JL, Agurs-Collins T, Meeker AK, Platz EA. Racial differences in maternal and umbilical cord blood leukocyte telomere length and their correlations. Cancer Causes Control. 2018 08; 29(8):759-767. PMID: 29980985; PMCID: PMC6083880; DOI: 10.1007/s10552-018-1054-8;
-
Palsgrove DN, Brosnan-Cashman JA, Giannini C, Raghunathan A, Jentoft M, Bettegowda C, Gokden M, Lin D, Yuan M, Lin MT, Heaphy CM, Rodriguez FJ. Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Mod Pathol. 2018 12; 31(12):1787-1800. PMID: 29973652; PMCID: PMC6269209; DOI: 10.1038/s41379-018-0103-x;
-
Bell WR, Meeker AK, Rizzo A, Rajpara S, Rosenthal IM, Flores Bellver M, Aparicio Domingo S, Zhong X, Barber JR, Joshu CE, Canto-Soler MV, Eberhart CG, Heaphy CM. A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease. Brain Pathol. 2019 01; 29(1):45-52. PMID: 29668072; PMCID: PMC8028494; DOI: 10.1111/bpa.12618;
-
Lai S, Heaphy CM, Rizzo AJ, Celentano DD, Gerstenblith G, Li J, Moore RD, Treisman G, Chen S, Foster P, Kickler T, Lai H. Cocaine use may induce telomere shortening in individuals with HIV infection. Prog Neuropsychopharmacol Biol Psychiatry. 2018 06 08; 84(Pt A):11-17. PMID: 29410247; PMCID: PMC5880737; DOI: 10.1016/j.pnpbp.2018.01.015;
-
Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate. 2018 02; 78(3):233-238. PMID: 29164645; PMCID: PMC5774625; DOI: 10.1002/pros.23462;
-
Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol. 2018 01; 244(1):11-24. PMID: 28888037; PMCID: PMC5801764; DOI: 10.1002/path.4980;
-
VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH, Heaphy CM. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. 2017 Jul; 125(7):544-551. PMID: 28371511; PMCID: PMC5511056; DOI: 10.1002/cncy.21857;
-
Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R. Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clin Cancer Res. 2017 Jun 15; 23(12):3150-3157. PMID: 28034905; PMCID: PMC5474132; DOI: 10.1158/1078-0432.CCR-16-1490;
-
Weber KA, Heaphy CM, Rohrmann S, Gonzalez B, Bienstock JL, Agurs-Collins T, Platz EA, Meeker AK. Influence of In Utero Maternal and Neonate Factors on Cord Blood Leukocyte Telomere Length: Clues to the Racial Disparity in Prostate Cancer? Prostate Cancer. 2016; 2016:3691650. PMID: 28070423; PMCID: PMC5192337; DOI: 10.1155/2016/3691650;
-
Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res. 2017 Mar 15; 23(6):1598-1606. PMID: 27663587; PMCID: PMC5354973; DOI: 10.1158/1078-0432.CCR-16-1147;
-
Rodriguez FJ, Vizcaino MA, Blakeley J, Heaphy CM. Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas. Acta Neuropathol. 2016 11; 132(5):761-763. PMID: 27650176; DOI: 10.1007/s00401-016-1619-0;
-
Hackeng WM, Brosens LA, Poruk KE, Noë M, Hosoda W, Poling JS, Rizzo A, Campbell-Thompson M, Atkinson MA, Konukiewitz B, Klöppel G, Heaphy CM, Meeker AK, Wood LD. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. Hum Pathol. 2016 10; 56:93-100. PMID: 27342911; DOI: 10.1016/j.humpath.2016.06.006;
-
Shekhani MT, Barber JR, Bezerra SM, Heaphy CM, Gonzalez Roibon ND, Taheri D, Reis LO, Guner G, Joshu CE, Netto GJ, Meeker AK. High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. Hum Pathol. 2016 08; 54:106-12. PMID: 27085557; DOI: 10.1016/j.humpath.2016.03.015;
-
Suryo Rahmanto Y, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IeM. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. J Biol Chem. 2016 Apr 29; 291(18):9690-9. PMID: 26953344; PMCID: PMC4850306; DOI: 10.1074/jbc.M115.707612;
-
Bodelon C, Heaphy CM, Meeker AK, Geller B, Vacek PM, Weaver DL, Chicoine RE, Shepherd JA, Mahmoudzadeh AP, Patel DA, Brinton LA, Sherman ME, Gierach GL. Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy. BMC Cancer. 2015 Oct 30; 15:823. PMID: 26519084; PMCID: PMC4628256; DOI: 10.1186/s12885-015-1860-2;
-
Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH. Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget. 2015 Sep 22; 6(28):25240-51. PMID: 26246475; PMCID: PMC4694828; DOI: 10.18632/oncotarget.4595;
-
Cesare AJ, Heaphy CM, O'Sullivan RJ. Visualization of Telomere Integrity and Function In Vitro and In Vivo Using Immunofluorescence Techniques. Curr Protoc Cytom. 2015 Jul 01; 73:12.40.1-31. PMID: 26132175; PMCID: PMC4862373; DOI: 10.1002/0471142956.cy1240s73;
-
Heaphy CM, Asch-Kendrick R, Argani P, Meeker AK, Cimino-Mathews A. Telomere length alterations unique to invasive lobular carcinoma. Hum Pathol. 2015 Aug; 46(8):1197-203. PMID: 26092192; DOI: 10.1016/j.humpath.2015.05.001;
-
Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Van Blarigan EL, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prev Res (Phila). 2015 Aug; 8(8):737-42. PMID: 25990087; PMCID: PMC4526348; DOI: 10.1158/1940-6207.CAPR-15-0097;
-
Heaphy CM, Gaonkar G, Peskoe SB, Joshu CE, De Marzo AM, Lucia MS, Goodman PJ, Lippman SM, Thompson IM, Platz EA, Meeker AK. Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Prostate. 2015 Aug 01; 75(11):1160-6. PMID: 25893825; PMCID: PMC4475463; DOI: 10.1002/pros.22997;
-
Julin B, Shui I, Heaphy CM, Joshu CE, Meeker AK, Giovannucci E, De Vivo I, Platz EA. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. Br J Cancer. 2015 Feb 17; 112(4):769-76. PMID: 25562437; PMCID: PMC4333493; DOI: 10.1038/bjc.2014.640;
-
Dogeas E, Karagkounis G, Heaphy CM, Hirose K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL, Choti MA. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. J Am Coll Surg. 2014 Apr; 218(4):628-35. PMID: 24655849; PMCID: PMC4332797; DOI: 10.1016/j.jamcollsurg.2014.01.001;
-
Hurwitz LM, Heaphy CM, Joshu CE, Isaacs WB, Konishi Y, De Marzo AM, Isaacs SD, Wiley KE, Platz EA, Meeker AK. Telomere length as a risk factor for hereditary prostate cancer. Prostate. 2014 Apr; 74(4):359-64. PMID: 24285042; PMCID: PMC4479489; DOI: 10.1002/pros.22755;
-
Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013 Nov; 123(11):4918-22. PMID: 24135135; PMCID: PMC3809798; DOI: 10.1172/JCI70354;
-
Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG. A glioblastoma neurosphere line with alternative lengthening of telomeres. Acta Neuropathol. 2013 Oct; 126(4):607-8. PMID: 24022427; PMCID: PMC3874856; DOI: 10.1007/s00401-013-1174-x;
-
-
Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 2013 Oct; 3(10):1130-41. PMID: 23779129; PMCID: PMC3797255; DOI: 10.1158/2159-8290.CD-13-0135;
-
Wood LD, Heaphy CM, Daniel HD, Naini BV, Lassman CR, Arroyo MR, Kamel IR, Cosgrove DP, Boitnott JK, Meeker AK, Torbenson MS. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol. 2013 Dec; 26(12):1586-93. PMID: 23640129; PMCID: PMC3974906; DOI: 10.1038/modpathol.2013.68;
-
Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Oliveira C, Justicia A, Griffith JK, Heaphy CM, Bernardo M, Kirkpatrick B. Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naïve patients with depression. Brain Behav Immun. 2013 Feb; 28:49-53. PMID: 23207109; PMCID: PMC3587123; DOI: 10.1016/j.bbi.2012.11.009;
-
Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas. Brain Pathol. 2013 May; 23(3):237-43. PMID: 22928601; PMCID: PMC3827727; DOI: 10.1111/j.1750-3639.2012.00630.x;
-
Butler KS, Hines WC, Heaphy CM, Griffith JK. Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas. Cancer Med. 2012 Oct; 1(2):165-75. PMID: 23342266; PMCID: PMC3544452; DOI: 10.1002/cam4.14;
-
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012 Jul; 3(7):709-22. PMID: 22869205; PMCID: PMC3443254; DOI: 10.18632/oncotarget.588;
-
de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol. 2012 Jul; 25(7):1033-9. PMID: 22575867; PMCID: PMC3547622; DOI: 10.1038/modpathol.2012.53;
-
Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011 Oct 25; 108(43):17773-8. PMID: 21987798; PMCID: PMC3203756; DOI: 10.1073/pnas.1110969108;
-
Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IeM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011 Oct; 179(4):1608-15. PMID: 21888887; PMCID: PMC3181356; DOI: 10.1016/j.ajpath.2011.06.018;
-
Wang Y, Meeker AK, Kowalski J, Tsai HL, Somervell H, Heaphy C, Sangenario LE, Prasad N, Westra WH, Zeiger MA, Umbricht CB. Telomere length is related to alternative splice patterns of telomerase in thyroid tumors. Am J Pathol. 2011 Sep; 179(3):1415-24. PMID: 21763260; PMCID: PMC3157225; DOI: 10.1016/j.ajpath.2011.05.056;
-
Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011 Jul 22; 333(6041):425. PMID: 21719641; PMCID: PMC3174141; DOI: 10.1126/science.1207313;
-
-
Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler KS, Joste NE, Bisoffi M, Griffith JK. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer. 2011 Sep 15; 129(6):1310-21. PMID: 21105047; PMCID: PMC3249233; DOI: 10.1002/ijc.25788;
-
Heaphy CM, Subhawong AP, Gross AL, Konishi Y, Kouprina N, Argani P, Visvanathan K, Meeker AK. Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. Mod Pathol. 2011 Feb; 24(2):194-200. PMID: 21057458; PMCID: PMC4416483; DOI: 10.1038/modpathol.2010.198;
-
Hong SM, Heaphy CM, Shi C, Eo SH, Cho H, Meeker AK, Eshleman JR, Hruban RH, Goggins M. Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Mod Pathol. 2011 Feb; 24(2):256-66. PMID: 20871595; PMCID: PMC3166222; DOI: 10.1038/modpathol.2010.181;
-
Heaphy CM, Fleet TM, Treat EG, Lee SJ, Smith AY, Davis MS, Griffith JK, Fischer EG, Bisoffi M. Organ-wide telomeric status in diseased and disease-free prostatic tissues. Prostate. 2010 Sep 15; 70(13):1471-9. PMID: 20687220; PMCID: PMC3920907; DOI: 10.1002/pros.21182;
-
Subhawong AP, Heaphy CM, Argani P, Konishi Y, Kouprina N, Nassar H, Vang R, Meeker AK. The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. Mod Pathol. 2009 Nov; 22(11):1423-31. PMID: 19734843; DOI: 10.1038/modpathol.2009.125;
-
Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol. 2009 Sep; 35(3):537-46. PMID: 19639174; DOI: 10.3892/ijo_00000365;
-
Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat. 2009 Nov; 118(2):229-39. PMID: 19685287; DOI: 10.1007/s10549-009-0504-0;
-
Treat EG, Heaphy CM, Massie LW, Bisoffi M, Smith AY, Davis MS, Griffith JK. Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology. 2010 Mar; 75(3):724-9. PMID: 19615720; PMCID: PMC2835834; DOI: 10.1016/j.urology.2009.04.032;
-
Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, Kirkpatrick B. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull. 2009 Mar; 35(2):437-42. PMID: 19279086; PMCID: PMC2659310; DOI: 10.1093/schbul/sbn169;
-
Heaphy CM, Bisoffi M, Joste NE, Baumgartner KB, Baumgartner RN, Griffith JK. Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Res Treat. 2009 Sep; 117(1):17-24. PMID: 18785004; PMCID: PMC2728157; DOI: 10.1007/s10549-008-0165-4;
-
Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN, Griffith JK. Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res. 2007 Dec 01; 13(23):7037-43. PMID: 18056180; DOI: 10.1158/1078-0432.CCR-07-0432;
-
Heaphy CM, Bisoffi M, Griffith JK. Diagnostic significance of allelic imbalance in cancer. Expert Opin Med Diagn. 2007 Oct; 1(2):159-68. PMID: 23489303; DOI: 10.1517/17530059.1.2.159;
-
Heaphy CM, Hines WC, Butler KS, Haaland CM, Heywood G, Fischer EG, Bisoffi M, Griffith JK. Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system. J Mol Diagn. 2007 Apr; 9(2):266-71. PMID: 17384220; PMCID: PMC1867446; DOI: 10.2353/jmoldx.2007.060115;
-
Liu Z, Wan G, Heaphy C, Bisoffi M, Griffith JK, Hu CA. A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model. Mol Cell Biochem. 2007 Mar; 297(1-2):179-87. PMID: 17119852
-
Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer. 2006 Nov 15; 119(10):2255-60. PMID: 16858685; DOI: 10.1002/ijc.22120;
-
Heaphy CM, Bisoffi M, Fordyce CA, Haaland CM, Hines WC, Joste NE, Griffith JK. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer. 2006 Jul 01; 119(1):108-16. PMID: 16450377; DOI: 10.1002/ijc.21815;
-
Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC, Griffith JK. Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat. 2006 Sep; 99(2):193-202. PMID: 16752076; DOI: 10.1007/s10549-006-9204-1;
-
Candia BJ, Hines WC, Heaphy CM, Griffith JK, Orlando RA. Protease nexin-1 expression is altered in human breast cancer. Cancer Cell Int. 2006 May 31; 6:16. PMID: 16737540; PMCID: PMC1501059; DOI: 10.1186/1475-2867-6-16;
-
Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol. 2005 Feb; 173(2):610-4. PMID: 15643274; DOI: 10.1097/01.ju.0000143195.49685.ce;
-
Fordyce CA, Heaphy CM, Griffith JK. Chemiluminescent measurement of telomere DNA content in biopsies. Biotechniques. 2002 Jul; 33(1):144-6, 148. PMID: 12139239; DOI: 10.2144/02331md02;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 6 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 10 |
| 2020 | 11 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 5 |
| 2024 | 5 |
2024 American Cancer Society Cancer Action Network:
Member
2023 North American Neuroendocrine Tumor Society:
Nominating Committee Member
2023 Neuroendocrine Tumor Research Foundation:
Pilot Grant Awardee
2022 Frontiers in Oncology:
Review Editor for Genitourinary Oncology
2022 North American Neuroendocrine Tumor Society (NANETS):
Chair of the Scientific Review & Research Committee
2022 Endocrine-Related Cancer:
Editorial Board Member
2021 Shipley Prostate Cancer Research Center at BU:
Executive Advisory Committee Member
2021 North American Neuroendocrine Tumor Society (NANETS):
Co-Chair of the Scientific Review & Research Committee
2021 Boston University:
CTSI Pilot Grant Awardee
2021 Johns Hopkins University School of Medicine:
Adjunct Assistant Professor in Oncology Center
2020 BU-BMC Cancer Center:
American Cancer Society BU-BMC Cancer Center Pilot and Feasibility Program Awardee
2020 Boston University School of Medicine:
Shipley Prostate Cancer Pilot Grant Awardee
2019 95th Annual American Association of Neuropathologists Meeting:
Moore Award for the Best Clinico-Pathologic Paper in Neuropathology
2016 North American Neuroendocrine Tumor Society:
Basic/Translational Science Investigator Award
2014 Patrick C. Walsh Prostate Cancer Research Fund:
Dr. and Mrs. Peter S. Bing Scholar Award
2014 Prostate Cancer Foundation:
Young Investigator Award
2013 Johns Hopkins Department of Pathology Young Investigator’s Day:
Award for Excellence in Translational Research
2012 Johns Hopkins Fellow Research Day:
1st Place for Basic Research
2011 Johns Hopkins Department of Pathology Young Investigator’s Day:
Award for Excellence in Translational Research
2011 United States and Canadian Academy of Pathology:
Stowell-Orbison Award
2007 American Urological Association Annual Meeting Travel Award
2004 American Association of Cancer Research Travel Award
2002 National Cancer Institute:
Cancer Research Training Fellowship; Laboratory of Cellular Carcinogenesis and Tumor Promotion